Published in Drug Law Weekly, November 18th, 2008
Based on these positive results, Teva will work with the U.S. Food and Drug Administration (FDA) to modify the AZILECT(R) label to reflect this data.
Selectivity was tested by evaluating the interaction between tyramine and rasagiline in healthy subjects. This...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.